Drug Trial Radar · NCT07649525
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,226
Planned (sponsor's estimate)
Start
Jul 3, 2026
Primary completion
Jun 2033
Study completion Jun 2037
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cancer Research UK; Blood Cancer UK; Johnson & Johnson
- First posted
- Jun 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
iFIT is a trial for newly diagnosed transplant-ineligible patients with the bone marrow cancer myeloma. These patients are generally older and have a lower level of fitness than others. Patients can take part if their doctor would otherwise recommend the standard NHS treatment daratumumab, lenalidomide and dexamethasone (DRd). After six months of DRd, the subsequent treatment a patient receives in iFIT is based on two factors: the patient's fitness level and treatment response. The trial compares different treatment strategies to determine whether outcomes can be improved for specific patient groups.
Conditions
- Multiple Myeloma (MM)
- Plasma Cell Leukemia (PCL)
Interventions
DaratumumabDrug
Participants will receive daratumumab by subcutaneous injection. Each cycle is 28 days.
LenalidomideDrug
Taken orally as capsules. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
DexamethasoneDrug
Taken as oral tablets, oral solution, or given by IV. Each cycle is 28 days. Dose can be adjusted for frailty and renal function.
TeclistamabDrug
Participants will receive teclistamab by subcutaneous injection. Each cycle is 28 days.
TalquetamabDrug
Participants will receive talquetamab by subcutaneous injection. Each cycle is 28 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- iFIT1: Progression-free survival (PFS)Time frame: From iFIT1 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation.
- iFIT2: Event-free survival (EFS)Time frame: From iFIT2 randomisation to EFS event, assessed up to a maximum of 6.5 years post-randomisation.
- iFIT3: Progression-free survival (PFS) and participant-reported overall health and quality of life (QoL) - co-primary outcomesTime frame: PFS: from iFIT3 randomisation to PFS event, assessed up to a maximum of 10.5 years post-randomisation. QoL: measured at the start of cycle 1 and after 6 28-day cycles of DRd induction, and further timepoints up to 30 months post-iFIT3 randomisation.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Bristol Haematology and Oncology Centre
Bristol, United Kingdom · Not yet recruiting
Eastbourne District General Hospital
Eastbourne, United Kingdom · Not yet recruiting
St James University Hospital
Leeds, United Kingdom · Not yet recruiting
The Clatterbridge Cancer Centre - Liverpool
Liverpool, United Kingdom · Recruiting
The Royal Marsden Hospital
London, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.